Download PDF
Thromb Haemost 1976; 36(01): 284-285
DOI: 10.1055/s-0038-1648037
Letter to the Editor
Schattauer GmbH

A Comparison of Two Methods for Measurement of von Willebrand’s Factor (Ristocetin Cofactor)

S. V Dowling
1   Department of Haematology, Royal Children’s Hospital, Parkville, Vic. 3052, Australia.
,
H Ekert
1   Department of Haematology, Royal Children’s Hospital, Parkville, Vic. 3052, Australia.
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Allain J. P, Cooper H. A, Wagner R. H, Brinkhous K. M. 1975; Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. Journal of Laboratory and Clinical Medicine 85: 318.
    PubMedGoogle Scholar
  • 2 Brinkhous K. M, Graham J. E, Cooper H. A, Allain J. P, Wagner R. H. 1975; Assay of von Willebrand factor in von Willebrand’s disease and hemophilia: use of a macroscopic platelet aggregation test. Thrombosis Research 6: 267.
    CrossrefPubMedGoogle Scholar
  • 3 Dowling S. V, Muntz R. H, D’Souza S, Ekert H. 1975; Ristocetin in the diagnosis of von Willebrand’s disease: A comparison of rate and percent of aggregation with levels of the plasma factor (s) necessary for ristocetin aggregation. Thrombosis et Diathesis Haemorrhagica 34: 465.
    PubMedGoogle Scholar
  • 4 Kirby E. P, Mills D. C. B. 1975; The interaction of bovine factor VIII with human platelets. Journal of Clinical Investigation 56: 491.
    CrossrefPubMedGoogle Scholar
  • 5 Macfarlane D. E, Stibbe J, Kirby E. P, Zucker M. B, Grant R. A, McPherson J. 1975; A method for assaying von Willebrand factor (ristocetin cofactor). Thrombosis et Diathesis Haemorrhagica 34: 306.
    PubMedGoogle Scholar
  • 6 Weiss H. J, Hoyer L. W, Rickles F. R, Varma A, Rogers J. 1973; Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. Journal of Clinical Investigation 52: 2708.
    CrossrefPubMedGoogle Scholar